AGEN Jan 2025 1.500 call
| Previous close | 0.0600 |
| Open | 0.0600 |
| Bid | 0.0000 |
| Ask | 0.0000 |
| Strike | 1.50 |
| Expiry date | 2025-01-17 |
| Day's range | 0.0600 - 0.0600 |
| Contract range | N/A |
| Volume | |
| Open interest | 1.25k |
- Business Wire
Nature Medicine Reports Agenus’ Novel Immunotherapy Demonstrates Clinical Activity Against a Deadly Form of Colorectal Cancer on the Rise in Americans Under 50
LEXINGTON, Mass., June 13, 2024--Agenus has published results from a groundbreaking clinical trial in Nature Medicine, revealing the potential of a novel immunotherapy combination for treating microsatellite stable metastatic colorectal cancer (MSS mCRC), a cancer type historically resistant to immunotherapy. This pioneering research, led by an international team of oncologists, focuses on the efficacy and safety of botensilimab (BOT), an Fc-enhanced anti-CTLA-4 antibody, in combination with bal
- Business Wire
Agenus Announces Virtual Annual Shareholders Meeting
LEXINGTON, Mass., June 04, 2024--Agenus Inc. ("Agenus") (NASDAQ: AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today announced that its Annual Shareholders Meeting will begin at 10:30 a.m. ET on June 11, 2024, and will be conducted in a virtual format only. Registration for attendees will start at 10:15 a.m. ET.
- Business Wire
Agenus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
LEXINGTON, Mass., May 24, 2024--Agenus Inc. ("Agenus") (Nasdaq: AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today announced that the Compensation Committee of Agenus’ Board of Directors granted inducement awards to Eric Olson, in connection with his appointment as Head of Regulatory. The Compensation Committee approved the awards pursuant to Agenus' 2015 Inducement Equity Plan and in accordance with Nasdaq Listing Rule 5635(c)(4).
